文献速递真菌感染细菌感染、耐药与抗菌药物医院感染防控

耳念珠菌各分支抗真菌耐药性差异的定量与定性分析及临床意义

How does antifungal resistance vary in Candida (Candidozyma) auris and its clades? Quantitative and qualitative analyses and their clinical implications.
PubMed 文献 · Clin Microbiol Infect · 2025-04-09

该综述汇总1031株耳念珠菌的药敏数据,分析六个分支的耐药谱。分支I和III对氟康唑耐药率最高,分别为94%和96%;分支IV对唑类和棘白菌素类均耐药;分支II、V、VI耐药率较低,分支VI对氟康唑完全敏感。阿尼芬净在各分支中耐药率最低(0%–3.67%)。作者强调需持续监测分支特异性耐药以优化治疗。

要点

  • 分支I和III对氟康唑耐药率分别达94%和96%,为最高。
  • 分支IV对唑类和棘白菌素类均耐药,呈多重耐药。
  • 阿尼芬净在各分支中耐药率0%–3.67%,体外活性最佳。

核心结论

  • 耳念珠菌六个分支的抗真菌耐药谱存在显著差异,分支I、III、IV的多重耐药(尤其对氟康唑和两性霉素B)给治疗带来严重挑战。
  • 持续全球监测和分支特异性管理策略对控制耳念珠菌感染至关重要,尤其针对高耐药分支。
  • 加强诊断能力和进一步基因组研究对理解耐药演变和改善治疗结局至关重要。

研究设计与样本

  • 本文为综述,通过PubMed、SciELO、Google Scholar和MEDLINE数据库进行综合文献检索,收集耳念珠菌菌株的MIC分布和分支 designation 数据,共纳入1031株耳念珠菌。

主要发现

  • 分支I和III亲缘关系密切,耐药率最高,对氟康唑耐药率分别为94%和96%。
  • 分支IV对唑类和棘白菌素类均显示耐药。
  • 分支II、V、VI耐药率较低,分支VI对氟康唑完全敏感。
  • 阿尼芬净在所有分支中耐药率范围为0%–3.67%。
  • 分支V和VI对所有评估的抗真菌药物完全敏感。

关键数值与推荐

  • 共纳入1031株耳念珠菌。
  • 分支I对氟康唑耐药率为94%。
  • 分支III对氟康唑耐药率为96%。
  • 阿尼芬净在所有分支中耐药率范围为0%–3.67%。

临床怎么用

  • 作者认为,分支特异性抗真菌耐药监测对于优化暴发期间的治疗选择是必要的。
  • 作者指出,持续全球监测和量身定制的管理策略对控制耳念珠菌感染至关重要,尤其在高耐药分支中。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Candida (Candidozyma) auris is a multidrug-resistant yeast that emerged as a significant health care-associated pathogen. It is classified as an urgent threat to public health due to the high resistance to available antifungal agents. Globally six distinct clades of C. auris have been identified with varying antifungal susceptibility patterns and geographical distributions. OBJECTIVES: The aim of this review is to investigate the (published) antifungal susceptibility profiles of different C. auris clades to identify those with a higher prevalence of resistance. SOURCES: A comprehensive literature review was conducted using PubMed, SciELO, Google Scholar, and MEDLINE databases to collect data on MIC distributions and clade designations of C. auris strains. CONTENT: A total of 1031 C. auris strains were included. Clades I and III, which are closely related phylogenetically, displayed the highest resistance rates, particularly to fluconazole, with 94% and 96% of isolates, respectively. Clade IV also exhibited resistance to both azoles and echinocandins. In contrast, clades II, V, and VI had lower resistance rates, with clade VI being entirely susceptible to fluconazole. Anidulafungin demonstrated the greatest efficacy across all clades, with resistance rates ranging from 0% to 3.67%. Furthermore, clades V and VI showed complete susceptibility to all antifungal agents evaluated. IMPLICATIONS: This study highlights significant variations in antifungal resistance profiles across the six C. auris clades. Clades I, III, and IV stand out because of their multidrug resistance, particularly to fluconazole and amphotericin B, posing serious challenges for treatment. Continuous global surveillance and tailored management strategies are essential for controlling C. auris infections, especially in highly resistant clades. Enhanced diagnostic capabilities and further genomic studies are critical to understanding the evolving nature of resistance in this emerging pathogen and improving therapeutic outcomes. Clade-specific antifungal resistance in C. auris requires monitoring to optimize therapy selection during outbreaks.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. da Silva KJG, Lucini F, Dos Santos RAC, et al. How does antifungal resistance vary in Candida (Candidozyma) auris and its clades? Quantitative and qualitative analyses and their clinical implications. Clin Microbiol Infect. 2025. PMID: 40216246. doi:10.1016/j.cmi.2025.04.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。